In the following, the online help texts for all data entry fields provided with any Endpoint summary record for this IUCLID section are listed. As to whether and to what extent endpoint summaries should be prepared, refer to the relevant guidance for the respective chemical programme, e.g., the Technical Guidance Document (TGD) on preparing the Chemical Safety Report under REACH in its most recent version.
For technical guidance on how to manage Endpoint summary records, see How to manage Endpoint summary records in sections 4 - 10, respectively. For details on data types, see What data types are available for input fields and how are they used?.
Enter a full short description of the most relevant endpoint data. This includes in principle the summary information that is compiled e.g. in the OECD Full SIDS Summary format or other endpoint summary formats. Provide only the most relevant details, which could be, depending on the cases, the test guideline used, test organism and exposure duration. Normally no reliability score needs to be indicated as it can be assumed that the studies identified are valid (reliability score 1 or 2). If this is not the case (for instance if the reliability of a published study cannot be assigned or if several less valid studies are used for a weight of evidence analysis), the reliability indicators should be specified.
Also several key studies can be referenced as applicable. However, the characterisation of the endpoint data should be kept as concise as possible. Examples of what could be entered here are as follows:
- Melting point: 54.6-55.8 °C at 1,013 hPa
- Water solubility: completely miscible
- pH: 6.9 (80 mg/l water) at 20°C (OECD TG105)
- Oxidation reduction potential: no data available
- Phototransformation in air: T1/2 = 9.32 x 10-2 yr (sensitizer: OH radical) (AOP Win v 1.86)
- Biodegradation in water: screening tests: Not readily biodegradable: 0 - 8% (BOD) in 28 days, 0 - 1% (HPLC) in 28 days (OECD TG 301C)
- Short-term toxicity to fish:
LC50 (96h) < 100 mg/l for Pimephales promelas (OECD TG 203)
LC50 (48h) = 3.2 mg/l for Oryzias latipes (OECD TG 203)
- Acute toxicity:
Dermal: LD50: > 2,000 mg/kg for rat (limit test)
- Genetic toxicity:
In vitro:
Gene mutation (Bacterial reverse mutation assay / Ames test): S. typhimurium TA 100: positive with and without metabolic activation; TA 1535: positive without metabolic activation (equivalent to OECD TG 471)
The field(s) under this heading (if provided) can be optionally completed in order to specify the key parameter(s) that may subsequently be used in the chemical safety assessment, classification and labelling or other. In order to enable the use of any specific software, only a minimum number of structured and hence, searchable fields are provided, in many cases only one.
Key parameters are intended to condense the data summarised in field "Full short description of relevant endpoint data" to one single numeric value or concluding remark (e.g. negative / positive) chosen from a drop-down list. Where a numeric field is provided, only a clear value can be entered, that is, no range and no less than or greater than qualifiers. Conversion to a predefined unit as indicated in the field label (e.g. mg/L) may be required.
If the key value is no clear number, but a range or preceded by <, <=, >, or >=, you may either leave this field empty or make up a value you consider most appropriate for the intended subsequent purpose. The rationale for any user-derived values should be described in field "Discussion" for the sake of transparency. Some non-exhaustive examples of user-derived parameters are as follows:
- Aquatic short-term L(E)C50 >100 mg/L (e.g. because only tested up to water solubility of the substance): it may be appropriate to assume 100 mg/L as worst case value.
- Aquatic long-term LOEC 1 mg/L (>10 and <20% effect): calculate NOEC as LOEC/2 and enter 0.5 mg/L in the field for NOEC.
- Acute oral LD50 >2000 mg/kg b.w. (because no LD50 was achieved in a limit test): enter 2000 mg/kg b.w.
In this rich text field, describe the assessment you have made for the given endpoint. Provide the rationale for the choice of the key study(ies) and the choice of the key parameter that, according to your judgement, characterise the endpoint. This includes a discussion of the key information identified and in some instances of studies which are considered to be unreliable, but give critical results. A discussion as to why they were discarded in favour of other studies should then be included. Vice versa, a weight of evidence analysis based on less reliable data or use of published data, the reliability of which cannot be judged because of limited reporting, should be justified.
If several studies were identified to be relevant for the assessment, discuss possible reasons for differing results if any, e.g. differences in purity / impurities of the test substance used, differences in the methods and test conditions, etc.
In the following, the online help texts for all data entry fields provided with any Endpoint study record for this IUCLID section are listed. For sections 4 to 10, these guidance notes are completely based on the so-called OECD Harmonised Templates (see Rationale behind IUCLID Endpoint Study Records - OECD harmonised templates in chapter chapter D.4.7.1 What is an Endpoint study record?)
IUCLID per se does not prescribe how detailed the study summaries should be recorded. Refer to the relevant guidance for the respective chemical regulatory programme thereof.
For technical guidance on how to manage Endpoint study records, see chapter D.4.7 How to manage Endpoint study records in sections 4 - 13. For details on data types, see chapter D.4.5 What data types are available for input fields and how are they used?
Under this main heading, fields are subsumed for identifying the purpose of the record (e.g., "key study"), the type of result (e.g., "experimental study"), data waiving indication (if any), reliability indication, and flags for indicating the regulatory purpose envisaged and/or any confidentiality restrictions. This kind of data characterise the relevance of a study summary and are therefore displayed on top of each Endpoint Study Record. For detailed guidance, refer to chapter D.4.7.7.1 Administrative data.
Indicate the bibliographic reference of the study report or publication the study summary is based on. Always enter the primary reference in the first block of fields (i.e. Sort no. = 1), if there are more than one reference to be cited. Copy this block of fields for specifying any other references related to this record (e.g. report of a preliminary study or other documentation). If results of a study report have been published, indicate the full citation of that publication(s) in addition to the reference of the original study.
Table E.436. Field Descriptions
| Reference type | Indicate the type of reference, e.g. "Study report" or "Publication". Select "Other company data" to characterise any unpublished information from a company other than a study report. Select "Grey literature" for any other unpublished information or "other:" and specify. |
| Author(s) (or transferred reference) (Author) | For ease of sorting and searchability use following convention: Surname, Initial (Example 1: White D, Ruehl KJ, Borman SA & Little J. Example 2: Hartley M & Murray W (avoid unnecessary full-stops, commas)). If no individuals are cited as authors, enter name of company or organisation or "Anon." as appropriate. Note that the complete bibliographic reference may appear in this field after migration of unstructured data from existing databases. |
| Year | Enter year of study report or publication. For a study report this field should be completed to include it in any searches, regardless of whether the complete date is given in field "Report date". |
| Title | Include the title of the report. For publications, include the title of the article of a journal or article/chapter of a book (e.g. handbook). |
| Bibliographic source | Not relevant for any study report. For publications or any other literature source (grey literature) specify the following type of information: (i) Title of scientific journal or book (e.g. if handbook); (ii) Volume of journal; (iii) Editor, publisher, place of publication for books or articles in books; (iv) Pagination. Example 1 (journal): J. Agric. Food Chem. 38: 215-227 Example 2 (handbook): In: Lyman WJ (ed.) Handbook of chemical property estimation methods. Environmental behavior of organic compounds. McGraw-Hill Book Company 15.1-15.34, New York. |
| Testing laboratory | Either manually enter the name of the testing laboratory or select it from the picklist. In either case, editing is possible. |
| Report no. | Specify the report number allocated by the testing laboratory. Note that any company-specific study number should be included in the respective field. |
| Owner company | Either manually enter the identity of the company who owns the data or select it from the picklist. In either case, editing is possible. |
| Company study no. | Specify any company study no. if there is such a number and if it is different from the report no. of the testing laboratory. Otherwise leave field empty. |
| Report date | Specify the complete date of the study report, e.g. "2005-05-12" for 12 May 2005. Note that subfield "Year" should be completed in any case for sorting and searching purposes. |
Select appropriate indication for data access. Enter "Not applicable" if the summary consists of information that is commonly accessible such as guidance on safe use.
Indicate as appropriate. Note: "yes" should be selected only if "Data submitter is data owner" or "Data submitter has Letter of Access". Options "yes, but willing to share" or "yes, but not willing to share" may be relevant for specific regulatory programmes where the submitter is requested to indicate whether he is willing to share studies (e.g. with vertebrates).
In the supplementary remarks field, include an explanation as appropriate, i.e. justification for denial of sharing the corresponding study or refer to a document attached that provides justification (e.g. "for justification see attached document X")
A cross-reference can be included to indicate that the same study is recorded in another record. Indicate the respective chapter and record ID and enter relevant explanatory text. This may be useful if specific endpoints of a given study are described in another chapter (e.g. results on reproduction toxicity in case of a combined repeated dose / reproduction toxicity study) or if more than one experiment is described by the same study report, but included in separate records.
Check with the relevant guidance document whether all the methodology details must be repeated or whether a cross-reference to the same study in another chapter may suffice.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.
Indicate the type of genotoxicity adressed, i.e. gene mutation, chromosome aberration, DNA damage and/or repair or genome mutation.
Note: This field may be redundant with the information given in field "Guideline", but is considered useful for searching reasons.
Indicate the type of study.
Note: This field may be redundant with the information given in field "Guideline", but is considered useful for searching reasons.Indicate the type of study.
Note: This field may be redundant with the information given in field "Guideline", but is considered useful for searching reasons.
Indicate according to which test guideline the study was conducted. If no test guideline was explicitly followed, but the methodology used is equivalent or similar to a specific guideline, you can indicate so in the "Qualifier" subfield preceding the field "Guideline".
Copy this block of fields for specifying more than one guideline (e.g. US EPA in addition to OECD guideline).
Table E.437. Field Descriptions
| Qualifier | Select appropriate qualifier, i.e. - "according to" (if a given test guideline was followed); - "equivalent or similar to" (if no test guideline was explicitly followed, but the methodology is equivalent or similar to a specific guideline); - "no guideline followed" (if none of above qualifiers apply. If so, fill in field "Principles of method if other than guideline"); - "no guideline available" (if so, fill in field "Principles of method if other than guideline"). - "no guideline required" (if so, fill in field "Principles of method if other than guideline"). |
| Guideline | Select the applicable test guideline, e.g. "OECD Guideline xxx". If the test guideline used is not listed, choose "other guideline:" and specify the test guideline in the related text field. In this text field, you can also enter any remarks as applicable, particularly: - To include any other title of the test guideline draft used, a subtitle, another version or update number and the year of update (For instance, different titles and/or numbers may exist for a given EU test guideline.); - To indicate if a the study was performed prior to the adoption of the test guideline specified; - To indicate if the methodology used was based on an extension of the test guideline specified. |
| Deviations from guideline (Deviations) | For robust study summaries or as requested by the regulatory programme, indicate if there are any deviations from the test guideline specified. If "yes" is selected, only briefly state relevant deviations in the supplementary remarks field (e.g. "other species used"); details should be described in the respective fields of the section MATERIALS AND METHODS. |
If no guideline was followed, include a description of the principles of the test protocol or estimated method used in the study. Details should be entered in appropriate distinct fields of section MATERIALS AND METHODS if available. Also provide a justification for using this method if appropriate.
If an estimation method was used (to be indicated in field "Test result type") state the equation(s) and/or computer software or other methods applied to calculate the value(s).
Indicate whether the study was conducted following Good Laboratory Practice or not. Select "yes (incl. certificate)" if a GLP certificate of a test facility is available. Select "yes" if a GLP compliance statement is available, but no information on a GLP certificate. You can give an explanation in the supplementary remarks field, e.g. for explaining why GLP was not complied with or for specifying which (national) GLP was followed.
Indicate if the test material used in the study is equivalent to the submission substance identity. If "yes" is selected, the corresponding identity is automatically entered in the subsequent block of fields "Test material identity".
If "no" is selected, identify the test material in the subsequent block of fields "Test material identity". In this case, also make sure that the information entered in field "Study result type" is consistent, i.e. "read-across from supporting substance (structural analogue or surrogate)".
NOTE: If a completed record is used for another submission, you may have to update both fields "Study result type" and "Test material equivalent to submission substance identity".
If the identity of the test material used for this study is not included in this block of fields automatically, indicate the identity for one or more appropriate identifiers, e.g. CAS number, CAS name, IUPAC name. Copy this block of fields as appropriate.
If another than the submission substance identity was selected erraneously, go back to field "Test material equivalent to submission substance identity" and select "yes". This will prompt automatic entry of the respective identifiers.
Table E.438. Field Descriptions
| Identifier | Select an appropriate identifier from drop-down list, e.g. "CAS number". Use "Other:" and specify, if identity according to a standard identifier is not known or if an additional chemical name or number is provided. |
| Identity | Select the corresponding substance identity from drop-down list or enter manually if the identity is not available from the list or if no list is provided for the type of identifier selected. |
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Note that any information that can be claimed confidential should be included in the subsequent field "Confidential details on test material".
Explanations:
- Name of test material (as cited in study report): only if different from any other identifiers provided in the preceding fields.
- Molecular formula (if other than submission substance): specify
- Molecular weight (if other than submission substance): specify
- Smiles notation (if other than submission substance): provide if available
- InChl (if other than submission substance): provide if available
- Structural formula attached as image file (if other than submission substance): see Fig.: only if different from submission substance. Indicate Fig. no. if a file is attached in field "Attached document", e.g. state "see Fig. 1".
- Substance type: indicate whether pure active substance, technical product, formulation or other.
- Physical state: indicate "gas", "solid" or "liquid" only if different from submission substance or if substance can occur in different physical states.
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Isomers composition: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: provide if available
- Expiration date of the lot/batch: provide if available
- Radiochemical purity (if radiolabelling): specify if applicable
- Specific activity (if radiolabelling): specify if applicable
- Locations of the label (if radiolabelling): specify if applicable
- Expiration date of radiochemical substance (if radiolabelling): specify if applicable
- Storage condition of test substance: specify if applicable
- Stability under test conditions: indicate if available
Enter any confidential information on the test material in this separate field. Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Explanations:
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: : provide if available
- Expiration date of the lot/batch: : provide if available
- Isomers composition: specify if applicable
Indicate the target gene (HPRT, XPRT, TK, ATPase, other: specify) only if necessary to characterise the test system.
Indicate the species and tester strain(s) used in the type of study indicated in the respective field above. Copy this field block for each tester strain.
Table E.439. Field Descriptions
| Species/strain | Select as appropriate. If not available from picklist, select "other" and specify. |
| Cell culture details (if applicable) (Details on mammalian cell lines (if applicable)) | For robust study summaries, describe relevant details on cell cultures if applicable. Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof. |
| Additional strain characteristics | For robust study summaries, indicate additional strain characteristics (e.g. "DNA-Polymerase-A-deficient") only if necessary to characterise the test system. Otherwise, leave this subfield empty. |
| Metabolic activation | Indicate whether metabolic activation was applied or not. Select "not applicable" for mammalian cell lines when no exogenous metabolic system is required. |
| Metabolic activation system | For robust study summaries, specify metabolic activation system, if any. Use predefined table to indicate substance used for induction, species and organ from which the activation system was prepared. Upload predefined table(s) if any in the rich text field "Any other information on results incl. tables" or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1"). Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof. |
Indicate the test concentrations without and with metabolic activation.
For robust study summaries or as requested by the regulatory programme, also include a detailed table in the rich text field "Any other information on results incl. tables". Upload predefined table(s) if any or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1").
Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Indicate whether and which vehicle(s)/solvent(s) was/were used or state "none" or "no data" as applicable. Indicate if different substances were used for tests with and without metabolic activation.
Provide the volume of vehicle/solvent in the medium (e.g. "DMSO (0.1 ml per 10 ml medium") and a justification for the choice of solvent/vehicle.
Also indicate whether vehicle (or negative) controls (i.e. consisting of culture medium or medium with solvent or vehicle alone) were tested.
Use freetext template and delete/add elements as appropriate. Note that the list of substances provided is not exhaustive.
Indicate whether vehicle, true negative and/or positive controls were tested. Repeat this block of fields as necessary, particularily if controls or different substances were used for tests with and without metabolic activation or for different tester strains. If necessary, indicate so in the supplementary remarks field. or in subfield "Remarks".
Table E.440. Field Descriptions
| Negative controls | Indicate whether negative controls (i.e. consisting of culture medium without solvent / vehicle or test substance, and otherwise treated in the same way as the treatment groups) were tested. Any explanations can be given in the supplementary remarks field. |
| Solvent / vehicle controls | Indicate whether solvent / vehicle controls (i.e. consisting of solvent or vehicle alone, without test substance, and otherwise treated in the same way as the treatment groups) were tested. Any explanations can be given in the supplementary remarks field. |
| True negative controls | Indicate whether true negative control(s) (i.e. substances with known lack of genotoxicity) was/were tested and specify the substance(s) in the supplementary remarks field. |
| Positive controls | Indicate whether positive controls (i.e. substances with known genotoxicity) were tested. If so, indicate what substance(s) was/were used as positive control(s) in following field. |
| Positive control substance | If applicable, indicate what substance was used as positive control. If several substances were used, repeat this block of fields accordingly. If different substances were used for tests with and without metabolic activation or for different tester strains, include a remark in subfield "Remarks". If other than the reference substance(s) specified in the test guidelines was/were used include a brief justification in the supplementary remarks field. Note that the list of substances provided is not exhaustive. |
| Remarks | Enter any remarks related to the recorded controls as appropriate. |
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Describe the evaluation criteria used in the study to judge if a substance is positive.
List parameters that were analysed and the statistical methods used; include a statement that the Reviewer considers the analyses used to be appropriate. If inappropriate, provide alternative/rationale.
In this field, you can enter any information on materials and methods, for which no distinct field is available, or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Include the main test results in this block of fields for each tester strain and metabolic activation system used. Multiply this block of fields as often as required. (Note: If only one strain was tested, subfield "Species/strain" may be left empty.)
In case of a robust study summary or as requested by the regulatory programme, also provide detailed tables on the genotoxicity and cytotoxicity results and refer to respective table no. (use predefined table if any).
Table E.441. Field Descriptions
| Species/strain | Indicate the species/strain or cell type tested. For the bacterial reverse mutation assay, "S. typhimurium TA 1535, TA 1537, TA 98 and TA 100" can be selected if all these strains were tested. Otherwise multiply this block of fields for each tester strain. |
| Metabolic activation | Indicate whether metabolic activation was applied or not. |
| Test system | Indicate "all strains/cell types tested" or select "strain/cell type: " and specify in the supplementary remarks field. |
| Genotoxicity | Indicate result of the test conducted with the tester strain(s) and the metabolic activation system specified. If positive or ambiguous, include concentration(s) in the supplementary remarks field or representative table. Upload predefined table(s) if any in the rich text field "Any other information on results incl. tables" or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1"). Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof. |
| Cytotoxicity | Indicate whether cytotoxicity was observed. If yes, specify the respective test concentration(s) in the supplementary remarks field or refer to results table. Upload predefined table(s) if any in the rich text field "Any other information on results incl. tables" or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1"). Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof. |
| Vehicle controls valid | Indicate whether test with vehicle control(s) (i.e. without test substance, with/without solvent) is valid. |
| Negative controls valid | Indicate whether test with true negative control(s) (i.e. substances with known lack of genotoxicity) is valid. |
| Positive controls valid | Indicate whether test with positive control(s), i.e. substance(s) with known genotoxicity, is valid. |
Enter any additional information that could be relevant for evaluating this study summary. Use freetext template and delete/add elements as appropriate. As an option you may include an excerpt from the study report.
In this field, you can enter any other remarks on results. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: Both the "Materials and methods" section and "Results" section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
In this field, you can enter any overall remarks or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Attach any background document that cannot be inserted in any rich text editor field, particularly image files (e.g. an image of a structural formula).
Copy this block of fields for attaching more than one file.
Table E.442. Field Descriptions
| Attached document | Upload file by clicking the upload icon. As appropriate, enter any additional information, e.g. language. The file name is displayed after uploading the document. |
| Remarks | As appropriate, include remarks, e.g. a short description of the content of the attached document if the file name is not self-explanatory. |
If required, an electronic copy of the full study report can be attached as WORD, pdf or other document type, which will not be integrated in any report, but must be handled as separate files.
Note: In the export administration you can indicate whether the attached files should be included in the data export or not.
Indicate overall interpretation of test results as given in the study report or as concluded by the submitter. Use supplementary remarks field for indicating if conclusions originally reported were changed by submitter or for any other explanations.
Copy this field for differentiating between results with / without metabolic activation.
If required by the respective national/regional programme, briefly summarise the relevant aspects of the study including the conclusions reached. If a specific format is prescribed, upload the respective freetext template if available from the drop-down list or copy it from the corresponding document.
Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
A Cross-reference to other study or other studies can be included which are considered relevant in the interpretation of the test results, e.g. for supporting the conclusion that an effect observed was not substance-related. Indicate the respective chapter(s) and record ID(s) and enter relevant explanatory text.
Such cross-references may be useful if it is considered relevant to discuss other results at the summary level of a single study. It should be noted that the overall appraisal of results from different studies is normally done in the hazard or risk assessment.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.
In the following, the online help texts for all data entry fields provided with any Endpoint study record for this IUCLID section are listed. For sections 4 to 10, these guidance notes are completely based on the so-called OECD Harmonised Templates (see Rationale behind IUCLID Endpoint Study Records - OECD harmonised templates in chapter chapter D.4.7.1 What is an Endpoint study record?)
IUCLID per se does not prescribe how detailed the study summaries should be recorded. Refer to the relevant guidance for the respective chemical regulatory programme thereof.
For technical guidance on how to manage Endpoint study records, see chapter D.4.7 How to manage Endpoint study records in sections 4 - 13. For details on data types, see chapter D.4.5 What data types are available for input fields and how are they used?
Under this main heading, fields are subsumed for identifying the purpose of the record (e.g., "key study"), the type of result (e.g., "experimental study"), data waiving indication (if any), reliability indication, and flags for indicating the regulatory purpose envisaged and/or any confidentiality restrictions. This kind of data characterise the relevance of a study summary and are therefore displayed on top of each Endpoint Study Record. For detailed guidance, refer to chapter D.4.7.7.1 Administrative data.
Indicate the bibliographic reference of the study report or publication the study summary is based on. Always enter the primary reference in the first block of fields (i.e. Sort no. = 1), if there are more than one reference to be cited. Copy this block of fields for specifying any other references related to this record (e.g. report of a preliminary study or other documentation). If results of a study report have been published, indicate the full citation of that publication(s) in addition to the reference of the original study.
Table E.443. Field Descriptions
| Reference type | Indicate the type of reference, e.g. "Study report" or "Publication". Select "Other company data" to characterise any unpublished information from a company other than a study report. Select "Grey literature" for any other unpublished information or "other:" and specify. |
| Author(s) (or transferred reference) (Author) | For ease of sorting and searchability use following convention: Surname, Initial (Example 1: White D, Ruehl KJ, Borman SA & Little J. Example 2: Hartley M & Murray W (avoid unnecessary full-stops, commas)). If no individuals are cited as authors, enter name of company or organisation or "Anon." as appropriate. Note that the complete bibliographic reference may appear in this field after migration of unstructured data from existing databases. |
| Year | Enter year of study report or publication. For a study report this field should be completed to include it in any searches, regardless of whether the complete date is given in field "Report date". |
| Title | Include the title of the report. For publications, include the title of the article of a journal or article/chapter of a book (e.g. handbook). |
| Bibliographic source | Not relevant for any study report. For publications or any other literature source (grey literature) specify the following type of information: (i) Title of scientific journal or book (e.g. if handbook); (ii) Volume of journal; (iii) Editor, publisher, place of publication for books or articles in books; (iv) Pagination. Example 1 (journal): J. Agric. Food Chem. 38: 215-227 Example 2 (handbook): In: Lyman WJ (ed.) Handbook of chemical property estimation methods. Environmental behavior of organic compounds. McGraw-Hill Book Company 15.1-15.34, New York. |
| Testing laboratory | Either manually enter the name of the testing laboratory or select it from the picklist. In either case, editing is possible. |
| Report no. | Specify the report number allocated by the testing laboratory. Note that any company-specific study number should be included in the respective field. |
| Owner company | Either manually enter the identity of the company who owns the data or select it from the picklist. In either case, editing is possible. |
| Company study no. | Specify any company study no. if there is such a number and if it is different from the report no. of the testing laboratory. Otherwise leave field empty. |
| Report date | Specify the complete date of the study report, e.g. "2005-05-12" for 12 May 2005. Note that subfield "Year" should be completed in any case for sorting and searching purposes. |
Select appropriate indication for data access. Enter "Not applicable" if the summary consists of information that is commonly accessible such as guidance on safe use.
Indicate as appropriate. Note: "yes" should be selected only if "Data submitter is data owner" or "Data submitter has Letter of Access". Options "yes, but willing to share" or "yes, but not willing to share" may be relevant for specific regulatory programmes where the submitter is requested to indicate whether he is willing to share studies (e.g. with vertebrates).
In the supplementary remarks field, include an explanation as appropriate, i.e. justification for denial of sharing the corresponding study or refer to a document attached that provides justification (e.g. "for justification see attached document X")
A cross-reference can be included to indicate that the same study is recorded in another record. Indicate the respective chapter and record ID and enter relevant explanatory text. This may be useful if specific endpoints of a given study are described in another chapter (e.g. results on reproduction toxicity in case of a combined repeated dose / reproduction toxicity study) or if more than one experiment is described by the same study report, but included in separate records.
Check with the relevant guidance document whether all the methodology details must be repeated or whether a cross-reference to the same study in another chapter may suffice.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.
Indicate the type of genotoxicity adressed, i.e. gene mutation, chromosome aberration, DNA damage and/or repair or genome mutation.
Note: This field may be redundant with the information given in field "Guideline", but is considered useful for searching reasons.
Indicate the type of study.
Note: This field may be redundant with the information given in field "Guideline", but is considered useful for searching reasons.
Indicate according to which test guideline the study was conducted. If no test guideline was explicitly followed, but the methodology used is equivalent or similar to a specific guideline, you can indicate so in the "Qualifier" subfield preceding the field "Guideline".
Copy this block of fields for specifying more than one guideline (e.g. US EPA in addition to OECD guideline).
Table E.444. Field Descriptions
| Qualifier | Select appropriate qualifier, i.e. - "according to" (if a given test guideline was followed); - "equivalent or similar to" (if no test guideline was explicitly followed, but the methodology is equivalent or similar to a specific guideline); - "no guideline followed" (if none of above qualifiers apply. If so, fill in field "Principles of method if other than guideline"); - "no guideline available" (if so, fill in field "Principles of method if other than guideline"). - "no guideline required" (if so, fill in field "Principles of method if other than guideline"). |
| Guideline | Select the applicable test guideline, e.g. "OECD Guideline xxx". If the test guideline used is not listed, choose "other guideline:" and specify the test guideline in the related text field. In this text field, you can also enter any remarks as applicable, particularly: - To include any other title of the test guideline draft used, a subtitle, another version or update number and the year of update (For instance, different titles and/or numbers may exist for a given EU test guideline.); - To indicate if a the study was performed prior to the adoption of the test guideline specified; - To indicate if the methodology used was based on an extension of the test guideline specified. |
| Deviations from guideline (Deviations) | For robust study summaries or as requested by the regulatory programme, indicate if there are any deviations from the test guideline specified. If "yes" is selected, only briefly state relevant deviations in the supplementary remarks field (e.g. "other species used"); details should be described in the respective fields of the section MATERIALS AND METHODS. |
If no guideline was followed, include a description of the principles of the test protocol or estimated method used in the study. Details should be entered in appropriate distinct fields of section MATERIALS AND METHODS if available. Also provide a justification for using this method if appropriate.
If an estimation method was used (to be indicated in field "Test result type") state the equation(s) and/or computer software or other methods applied to calculate the value(s).
Indicate whether the study was conducted following Good Laboratory Practice or not. Select "yes (incl. certificate)" if a GLP certificate of a test facility is available. Select "yes" if a GLP compliance statement is available, but no information on a GLP certificate. You can give an explanation in the supplementary remarks field, e.g. for explaining why GLP was not complied with or for specifying which (national) GLP was followed.
Indicate if the test material used in the study is equivalent to the submission substance identity. If "yes" is selected, the corresponding identity is automatically entered in the subsequent block of fields "Test material identity".
If "no" is selected, identify the test material in the subsequent block of fields "Test material identity". In this case, also make sure that the information entered in field "Study result type" is consistent, i.e. "read-across from supporting substance (structural analogue or surrogate)".
NOTE: If a completed record is used for another submission, you may have to update both fields "Study result type" and "Test material equivalent to submission substance identity".
If the identity of the test material used for this study is not included in this block of fields automatically, indicate the identity for one or more appropriate identifiers, e.g. CAS number, CAS name, IUPAC name. Copy this block of fields as appropriate.
If another than the submission substance identity was selected erraneously, go back to field "Test material equivalent to submission substance identity" and select "yes". This will prompt automatic entry of the respective identifiers.
Table E.445. Field Descriptions
| Identifier | Select an appropriate identifier from drop-down list, e.g. "CAS number". Use "Other:" and specify, if identity according to a standard identifier is not known or if an additional chemical name or number is provided. |
| Identity | Select the corresponding substance identity from drop-down list or enter manually if the identity is not available from the list or if no list is provided for the type of identifier selected. |
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Note that any information that can be claimed confidential should be included in the subsequent field "Confidential details on test material".
Explanations:
- Name of test material (as cited in study report): only if different from any other identifiers provided in the preceding fields.
- Molecular formula (if other than submission substance): specify
- Molecular weight (if other than submission substance): specify
- Smiles notation (if other than submission substance): provide if available
- InChl (if other than submission substance): provide if available
- Structural formula attached as image file (if other than submission substance): see Fig.: only if different from submission substance. Indicate Fig. no. if a file is attached in field "Attached document", e.g. state "see Fig. 1".
- Substance type: indicate whether pure active substance, technical product, formulation or other.
- Physical state: indicate "gas", "solid" or "liquid" only if different from submission substance or if substance can occur in different physical states.
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Isomers composition: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: provide if available
- Expiration date of the lot/batch: provide if available
- Radiochemical purity (if radiolabelling): specify if applicable
- Specific activity (if radiolabelling): specify if applicable
- Locations of the label (if radiolabelling): specify if applicable
- Expiration date of radiochemical substance (if radiolabelling): specify if applicable
- Storage condition of test substance: specify if applicable
- Stability under test conditions: indicate if available
Enter any confidential information on the test material in this separate field. Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Explanations:
- Analytical purity: specify in %
- Impurities (identity and concentrations): specify
- Composition of the test material, percentage of components: specify if applicable
- Purity test date: provide if available
- Lot/batch No.: : provide if available
- Expiration date of the lot/batch: : provide if available
- Isomers composition: specify if applicable
Select name of species. If not available from picklist, select "other" and specify.
Select as appropriate. If not available from picklist, select "other" and specify.
Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Explanations:
- Diet: Describe type of diet (e.g. conventional laboratory diet / caloric restriction) and whether it was provided ad libitum.
- Water: Describe type (e.g. drinking water) and whether it was provided ad libitum.
- IN-LIFE DATES: If required, specify the in-life dates (i.e. the phase of a study following treatment in which the test system is alive/growing).
Select route of administration as appropriate, usually "oral: gavage". If another route was used, provide a justification and reasoning in field "Details on exposure". In the case of an inhalation study, also specify if "nose only" or other.
Indicate whether vehicle(s)/solvent(s) was/were used and specify the substance(s) or state "none" if no vehicle/solvent was used or "no data" if not available from the study report or publication. Provide a justification for the choice of solvent/vehicle. Provide further details as appropriate.
Use freetext template and delete/add elements as appropriate. Note that the list of substances provided is not exhaustive.
Select freetext template for the respective route of administration and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Indicate duration in days, weeks or months, e.g. "5 days" or "10 weeks".
Indicate the frequency of the administration of doses to the test animals (e.g., "once" or "daily injections" or "2 doses per day, 7 days per week").
Indicate observation period (in days, weeks, months) after last exposure to the test material.
Indicate the dose or concentration levels applied and the basis of quantity used. Copy this block of fields if the dose/concentration levels were determined on more than one basis of quantity as appropriate.
Table E.446. Field Descriptions
| Doses / concentrations (no label) | Indicate the doses or concentrations including unit applied to the test animals, e.g. 0, 112, 220, 523 mg/kg bw/day. You may enter explanatory text, e.g., indicate if the study was a limit test.. |
| Basis | Indicate whether doses/concentrations are based on nominal or actually ingested or analytically measured values. In the supplementary remarks field provide further details as appropriate. |
Enter value or specify if different number of animals were used per sex and/or dose level or for the pilot, range-finding and main study.
For robust study summaries or as requested by the regulatory programme, also include a detailed table on the animal assignment in the rich text field "Any other information on results incl. tables". Upload predefined table(s) if any or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1").
Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Indicate whether and what type of concurrent control groups were used. If not available from picklist, select "other" and specify. Copy field if more than one type of control was used.
Indicate what substance(s) was/were used as positive control(s) or state "none" if no positive controls were used or "no data" if not available from the study report or publication. If other than the reference substance(s) specified in the test guidelines was/were used include a brief justification. Also provide information on the route of administration and doses either under separate headings or in parentheses after the control substance(s) specified.
Use freetext template and delete/add elements as appropriate. Note that the list of substances provided is not exhaustive.
Indicate tissues and cell types examined including the number of cells analysed per animal. Also note if examinations were not performed with tissues or cells from all animals studied.
For robust study summaries or as requested by the regulatory programme, also include a detailed table in the rich text field "Any other information on results incl. tables". Upload predefined table(s) if any or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1").
Indicate any relevant details to characterise the test system and test protocol used. Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Describe the evaluation criteria used in the study to judge if a substance is positive.
List parameters that were analysed and the statistical methods used; include a statement that the Reviewer considers the analyses used to be appropriate. If inappropriate, provide alternative/rationale.
In this field, you can enter any information on materials and methods, for which no distinct field is available, or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Include the main test results in this block of fields. Multiply this block of fields as often as required, e.g. for recording different results for both sexes used.
For robust study summaries or as requested by the regulatory programme, also include a detailed table on the genotoxicity and toxicity results in the rich text field "Any other information on results incl. tables". Upload predefined table(s) if any or adapt table(s) from study report. Use table numbers in the sequence in which you refer to them in the Remarks text (e.g. "... see Table 1").
Note: Specific tables may be required. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
Table E.447. Field Descriptions
| Sex | Select from drop-down list. |
| Genotoxicity | Indicate if there was evidence of genotoxicity. If result is considered positive or ambiguous, include dose(s) in the supplementary remarks field or representative table, e.g. predefined table or an excerpt from the study report. |
| Toxicity | Indicate whether signs of toxicity were observed or not. If yes, briefly describe the in life animal observations and the effects by dose in the supplementary remarks field (e.g. "significantly decreased body weight gain in the high dose group). If necessary include further details in field "Additional information on results". |
| Vehicle controls valid | Indicate whether test with vehicle control(s) (i.e. without test substance, with/without solvent) is valid. |
| Negative controls valid | Indicate whether test with true negative control(s) (i.e. substances with known lack of genotoxicity) is valid. |
| Positive controls valid | Indicate whether test with positive control(s), i.e. substance(s) with known genotoxicity, is valid. |
Briefly describe the results of results of range-finding study if any. For the definitiv study, provide further details on results. Use freetext template and delete/add elements as appropriate. Enter any details that could be relevant for evaluating this study summary or that are requested by the respective regulatory programme.
Particularly with comprehensive data, include a table and refer to respective table no. (use predefined table if any). Narrative accompanying such tabular data should address the toxicological significance of the results and not repeat what is presented in the table(s).
Note: Depending on the regulatory programme some form of a table may be mandatory. Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
In this field, you can enter any other remarks on results. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: Both the "Materials and methods" section and "Results" section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
In this field, you can enter any overall remarks or transfer free text from other databases. You can also open a rich text editor and create formatted text and tables or insert and edit any excerpt from a word processing or spreadsheet document, provided it was converted to the HTML format.
Note: One rich text editor field each is provided for the MATERIALS AND METHODS and RESULTS section. In addition the fields "Overall remarks" and "Executive summary" allow rich text entry.
Attach any background document that cannot be inserted in any rich text editor field, particularly image files (e.g. an image of a structural formula).
Copy this block of fields for attaching more than one file.
Table E.448. Field Descriptions
| Attached document | Upload file by clicking the upload icon. As appropriate, enter any additional information, e.g. language. The file name is displayed after uploading the document. |
| Remarks | As appropriate, include remarks, e.g. a short description of the content of the attached document if the file name is not self-explanatory. |
If required, an electronic copy of the full study report can be attached as WORD, pdf or other document type, which will not be integrated in any report, but must be handled as separate files.
Note: In the export administration you can indicate whether the attached files should be included in the data export or not.
Indicate overall interpretation of test results as given in the study report or as concluded by the submitter. Use supplementary remarks field for indicating if conclusions originally reported were changed by submitter or for any other explanations.
If required by the respective national/regional programme, briefly summarise the relevant aspects of the study including the conclusions reached. If a specific format is prescribed, upload the respective freetext template if available from the drop-down list or copy it from the corresponding document.
Consult the programme-specific guidance (e.g. OECD HPVC, Pesticides NAFTA or EU REACH) thereof.
A Cross-reference to other study or other studies can be included which are considered relevant in the interpretation of the test results, e.g. for supporting the conclusion that an effect observed was not substance-related. Indicate the respective chapter(s) and record ID(s) and enter relevant explanatory text.
Such cross-references may be useful if it is considered relevant to discuss other results at the summary level of a single study. It should be noted that the overall appraisal of results from different studies is normally done in the hazard or risk assessment.
Note that any such cross-reference may become useless if a record is either printed or exchanged on its own.